Get the Stockscreener App
1.55
5.28%
0.13
Novabay Pharmaceuticals Inc stock is traded at $1.55, with a volume of 37,207.
It is up +5.28% in the last 24 hours and down -2.29% over the past month.
NovaBay Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets non-antibiotic and anti-infective products for the eye care market in the United States, China, and internationally. It offers Avenova, a prescription product for cleansing and removing foreign materials, including microorganisms and debris from skin around the eye; NeutroPhase for wound care market; CelleRx for the aesthetic dermatology market; Aganocide compounds patented synthetic molecules for use against bacteria, viruses, and fungi; auriclosene irrigation solution for urology; and intelli-Case, a device for soft and rigid gas permeable contact lenses. NovaBay Pharmaceuticals, Inc. has collaboration and license agreement with Virbac to develop auriclosene, a proprietary compound for veterinary markets. The company was formerly known as NovaCal Pharmaceuticals, Inc. and changed its name to NovaBay Pharmaceuticals, Inc. in February 2007. NovaBay Pharmaceuticals, Inc. was incorporated in 2000 and is based in Emeryville, California.
See More
Previous Close:
$1.42
Open:
$1.43
24h Volume:
37,207
Relative Volume:
0.06
Market Cap:
$40.23M
Revenue:
$521.00K
Net Income/Loss:
$-8.53M
P/E Ratio:
-0.6017
EPS:
-2.5762
Net Cash Flow:
$-7.71M
1W Performance:
+22.54%
1M Performance:
-2.29%
6M Performance:
-86.35%
1Y Performance:
-50.98%
1-Day Range:
$1.43
$1.54
1-Week Range:
$1.13
$1.75
52-Week Range:
$1.11
$99.75
Novabay Pharmaceuticals Inc Stock (NBY) Company Profile
Name
Novabay Pharmaceuticals Inc
Sector
Industry
Phone
510-899-8800
Address
2000 Powell Street, Suite 1150, Emeryville, CA
Compare NBY vs VRTX, REGN, ALNY, ARGX, INSM
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NBY
Novabay Pharmaceuticals Inc
|
1.54 | 37.10M | 521.00K | -8.53M | -7.71M | -2.5762 |
VRTX
Vertex Pharmaceuticals Inc
|
451.39 | 115.58B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
754.55 | 79.23B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
329.82 | 43.59B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
687.64 | 43.26B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
147.26 | 31.97B | 606.42M | -1.28B | -997.58M | -6.403 |
Novabay Pharmaceuticals Inc Stock (NBY) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-18-19 | Initiated | Ladenburg Thalmann | Buy |
| Jul-06-18 | Reiterated | H.C. Wainwright | Buy |
| Nov-15-17 | Reiterated | Laidlaw | Buy |
| Jun-05-17 | Initiated | ROTH Capital | Buy |
| Mar-27-17 | Initiated | Laidlaw | Buy |
| Feb-06-17 | Initiated | Rodman & Renshaw | Buy |
| Mar-07-16 | Downgrade | Maxim Group | Buy → Hold |
| Dec-14-15 | Reiterated | Maxim Group | Buy |
| Apr-30-15 | Resumed | Maxim Group | Buy |
| Mar-06-13 | Initiated | Ascendiant Capital Markets | Strong Buy |
| Jan-03-08 | Initiated | Dawson James | Speculative Buy |
View All
Novabay Pharmaceuticals Inc Stock (NBY) Latest News
NovaBay rebrands to Stablecoin Development Corp in full crypto pivot—pharma company's stock climbs 19% - MSN
Aug Macro: Can NovaBay Pharmaceuticals Inc beat the S P 5002026 Analyst Calls & Fast Exit Strategy with Risk Control - baoquankhu1.vn
NovaBay Rebrands To Stablecoin Development Corp In Full Crypto Pivot— Pharma Company's Stock Climbs 19% - Sahm
NovaBay Pharmaceuticals (NBY) Soars 19% Following Stablecoin Transformation Announcement - mexc.co
NovaBay Pharmaceuticals (NBY) Stock Jumps 19% on Stablecoin Pivot - MEXC
Eyecare biotech jumps 19% after stablecoin-focused rebrand - TradingView
NovaBay Pharmaceuticals Pivots to Stablecoins in Rebrand - Yahoo Finance
Pharmaceutical Stock Jumps 26% on Crypto Pivot Plan - Blockonomi
Biotech stock NovaBay jumps 19% amid pivot, rebrand to Stablecoin Development Corporation - The Block
Pharmaceutical stock surges 26% after crypto pivot - thestreet.com
NovaBay Rebrands as 'Stablecoin Development Corporation' With Nearly 9% of SKY Supply - thedefiant.io
Stablecoin Development Corp (SDEV): Former NovaBay Completes $147M SKY Token Acquisition and Corporate Rebrand - Blockonomi
NovaBay Pharmaceuticals to Rebrand as Stablecoin Development Corporation, Announces SKY Token Holdings and NYSE Ticker Change to SDEV 121314181920 - Minichart
NovaBay Pharmaceuticals shares are trading hi... - Benzinga
NovaBay Pharma Becomes SDEV, Bets $134M on Sky Protocol Token - Whalesbook
NovaBay Pharmaceuticals (NBY) Stock: Rebrands as Stablecoin Development Corp, Acquires $147M in SKY Tokens - CoinCentral
NovaBay Pharmaceutical (NBY) pivoting to crypto - CoinDesk
NovaBay Rebrands To Stablecoin Development Corp, Shares Jump 12 Percent - Yahoo Finance
NovaBay Pharmaceuticals Announces Name Change to Stablecoin Development Corporation, Reports Initial Staking Rewards, and Provides SKY Token Holdings Update - Bitget
NovaBay Pharmaceuticals Announces Name Change to Stablecoin Development Corporation, Reports ... - Bluefield Daily Telegraph
After $134M deal, NovaBay rebrands around 2.06B SKY tokens - Stock Titan
If You Invested $1,000 in Novabay Pharma (NBY) - Stock Titan
NBY Stock Price, Quote & Chart | NOVABAY PHARMACEUTICALS INC (NYSEARCA:NBY) - ChartMill
NovaBay Pharmaceuticals, Inc. 2025 Annual Report: Financials, Stock Warrants, Preferred Stock, and Corporate Actions - Minichart
NovaBay Pharmaceuticals 10-K: $0.6M Revenue, $(3.80) EPS, heavy net loss - TradingView
NovaBay (NYSE: NBY) pivots from pharma to SKY token and digital assets - Stock Titan
Taxes of NovaBay Pharmaceuticals, Inc. – FWB:B9P1 - TradingView
Total assets of NovaBay Pharmaceuticals, Inc. – GETTEX:B9P1 - TradingView
Non-controlling/minority interest of NovaBay Pharmaceuticals, Inc. – FWB:B9P1 - TradingView
Preferred dividends of NovaBay Pharmaceuticals, Inc. – FWB:B9P1 - TradingView
Preferred dividends of NovaBay Pharmaceuticals, Inc. – MUN:B9P1 - TradingView
Net income of NovaBay Pharmaceuticals, Inc. – MUN:B9P1 - TradingView
NovaBay Pharmaceuticals shareholders approve charter amendments and stock issuance By Investing.com - Investing.com Nigeria
EBITDA margin % of NovaBay Pharmaceuticals, Inc. – MUN:B9P1 - TradingView
Asset turnover of NovaBay Pharmaceuticals, Inc. – MUN:B9P1 - TradingView
Book value per share of NovaBay Pharmaceuticals, Inc. – MUN:B9P1 - TradingView
Total debt per share of NovaBay Pharmaceuticals, Inc. – MUN:B9P1 - TradingView
Revenue per share of NovaBay Pharmaceuticals, Inc. – MUN:B9P1 - TradingView
Operating margin % of NovaBay Pharmaceuticals, Inc. – MUN:B9P1 - TradingView
Return on invested capital % of NovaBay Pharmaceuticals, Inc. – MUN:B9P1 - TradingView
CapEx per share of NovaBay Pharmaceuticals, Inc. – MUN:B9P1 - TradingView
Operating cash flow per share of NovaBay Pharmaceuticals, Inc. – MUN:B9P1 - TradingView
Tangible book value per share of NovaBay Pharmaceuticals, Inc. – MUN:B9P1 - TradingView
Enterprise value to EBITDA ratio of NovaBay Pharmaceuticals, Inc. – MUN:B9P1 - TradingView
Non-operating income (total) of NovaBay Pharmaceuticals, Inc. – MUN:B9P1 - TradingView
Gross profit of NovaBay Pharmaceuticals, Inc. – FWB:B9P1 - TradingView
Diluted shares outstanding of NovaBay Pharmaceuticals, Inc. – FWB:B9P1 - TradingView
NovaBay Pharmaceuticals Approves Issuance of 837 Million Shares and 2026 Equity Incentive Plan in Shareholder Vote - Minichart
NovaBay Pharmaceuticals shareholders approve charter amendments and stock issuance - Investing.com UK
NovaBay Pharma Expands Share Capital and Governance Flexibility - TipRanks
NovaBay (NYSE: NBY) OKs 5B share authorization and charter changes - Stock Titan
Novabay Pharmaceuticals Inc Stock (NBY) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.99%
3.03%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):